New hope for ALK lung cancer: first human trial of AQUA07 begins
NCT ID NCT07617337
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the body handles the drug. Participants must have already tried at least one ALK-targeted therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AQUA07 (oral drug) and lorlatinib (oral drug)
- What this could lead to
- If successful, this could lead to a new treatment option for people with ALK-positive lung cancer who have already tried other therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 102 participants, so it is primarily testing safety and dosing. It is too soon to know if the drug will work or have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart ALK-Positive lung cancer?
- New drug cocktail aims to outsmart resistant lung cancer
- Antidepressant may ease brain fog from lung cancer drug
- Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
- New pill shows promise against tough lung cancer
- New program aims to ease distress for advanced lung cancer patients